Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery.

Fu, Xinping; Rivera, Armando; Tao, Lihua; Zhang, Xiaoliu

Fu, Xinping; Rivera, Armando; Tao, Lihua; Zhang, Xiaoliu.

Affiliation

Fu X; Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX.

Int J Cancer ; 133(10): 2483-92, 2013 Nov 15.

Article in En | MEDLINE | ID: mdl-23661285

Subject(s)

Melanoma, Experimental/blood supply; Melanoma, Experimental/therapy; Nanoparticles/administration & dosage; T-Lymphocytes/physiology; Amino Acid Sequence; Animals; Antigens, Neoplasm/biosynthesis; Antigens, Neoplasm/genetics; Blood Vessels/pathology; Cell Line; Cell Line, Tumor; Human Umbilical Vein Endothelial Cells/pathology; Humans; Integrin alphaVbeta3/metabolism; Male; Melanoma, Experimental/metabolism; Melanoma, Experimental/pathology; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Mutant Chimeric Proteins/biosynthesis; Mutant Chimeric Proteins/genetics; Neovascularization, Pathologic/drug therapy; Neovascularization, Pathologic/genetics; Neovascularization, Pathologic/metabolism; Neovascularization, Pathologic/pathology; Receptors, Antigen/metabolism; T-Lymphocytes/immunology

Key words

T cells; chimeric antigen receptor; echistatin; tumor neovasculature; αvß3 integrin

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma, Experimental / T-Lymphocytes / Nanoparticles Limits: Animals / Humans / Male Language: En Journal: Int J Cancer Year: 2013 Type: Article

Fulltext

XML

PubMed Links

Search on Google